Released Nov 14, 2018, after the close
10-Q filed Nov 14, 2018, 45 days after period end · 0001564590-18-029555
Q3 2018 · 10-Q
Revenue$7.84M$7.84M −55.2% vs Q3 2017+37.4% vs Q2 2018
Net Income-$10.24M-$10.24M N/M vs Q3 2017N/M vs Q2 2018
EPS Diluted-$21.26-$21.26 N/M vs Q3 2017N/M vs Q2 2018
Operating Income-$10,157,000N/M
Operating Cash Flowderived$47,573,000—
Free Cash Flowderived$47,214,000—
Margins · derived
Operating margin-129.6%−123.5 pt vs Q3 2017
Net margin-130.6%−122.5 pt vs Q3 2017
What the release said
The release
Same quarter
| Metric | Q3 2018 | Q3 2017 |
|---|---|---|
| Revenue | $7.84M | $17.50M |
| Net Income | -$10.24M | -$1.42M |
| EPS Diluted | -$21.26 | -$3.14 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR